IDT Biologika is a leading global CDMO providing End-to-End services in the Development and Manufacture of Viral Vaccines, Gene & Immune Therapeutics and aseptic Fill-Finish of Sterile Injectables.
Our mission is to support pharmaceutical and biotech companies to develop and commercialize their therapeutic products, allowing patients to benefit from life-saving treatments, worldwide.
With a combination of innovative technologies, world-class manufacturing solutions, scientific expertise and process excellence we are delivering for clinical and commercial programs for over three decades.
First point of contact for American customers to discover and utilize our end-to-end services in contract development and manufacturing of vaccines, gene & immune therapeutics and sterile injectables.
Year Founded 1921
1,600
employees
2 BSL-2 Sites
Worldwide Services for the global biopharmaceutical industry and governments
Over 30 years of experience in commercial filling of pharmaceuticals
More than 200 development, clinical and commercial projects in recent years
Over € 600 m
invested since 1993, including € 400 m since 2011
More than a century of experience in development and production of vaccines
Approvals
EMA, FDA, ANVISA
First German company which has its pandemic readiness confirmed by the German government.
17 – 20 March 2025
IDT Suite #2201 at the Benjamin Royal Sonesta, New York City
If you want to further your career with a global leader in vaccines, cell and gene therapeutics, and other biologics CDMO services, visit IDT Biologika’s careers section.
Let us help you with your project. To ensure, we have the information we need, please fill out the form.
You are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information